Greve Jonasson (liquornose46)

96, 95% confidence interval [CI]=1.3-6.9; p= 0.012), and tumor histologic type (clear cell/endometrioid vs. mucinous; OR32.8, 95% CI=6.9-154.8, p< 0.001; clear cell/endometrioid vs. serous OR 48.1, 95% CI=8.8-261.8, p< 0.001) were independent risk factors for an upgrade of the permanent diagnosis from a BOT to ovarian carcinoma. An elevated CA-125 level (over 136 U/mL) and tumor histologic type (clear cell and endometrioid subtypes) were associated with an upgrade in the diagnosis of ovarian tumor from a BOT on frozen section to a permanent diagnosis of malignancy. An elevated CA-125 level (over 136 U/mL) and tumor histologic type (clear cell and endometrioid subtypes) were associated with an upgrade in the diagnosis of ovarian tumor from a BOT on frozen section to a permanent diagnosis of malignancy. Neratinib has efficacy in central nervous system (CNS) metastases from HER2-positive metastatic breast cancer (MBC). We report outcomes among patients with CNS metastases at baseline from the phase III NALA trial of neratinib plus capecitabine (N+C) versus lapatinib plus capecitabine (L+C). NALA was a randomized, active-controlled trial in patients who received two or more previous HER2-directed regimens for HER2-positive MBC. Patients with asymptomatic/stable brain metastases (treated or untreated) were eligible. Patients were assigned to N+C (neratinib 240 mg per day, capecitabine 750 mg/m twice daily) or L+C (lapatinib 1,250 mg per day, capecitabine 1,000 mg/m twice daily) orally. Independently adjudicated progression-free survival (PFS), overall survival (OS), and CNS endpoints were considered. Of 621 patients enrolled, 101 (16.3%) had known CNS metastases at baseline (N+C, n= 51; L+C, n= 50); 81 had received prior CNS-directed radiotherapy and/or surgery. In the CNS subgroup, mean PFS through 2plus capecitabine. These findings build on previous phase II and III studies describing efficacy of neratinib in the prevention and treatment of CNS metastases, and support a role for neratinib as a systemic treatment option in the management of patients with HER2-positive brain metastases following antibody-based HER2-directed therapies. In a subgroup of patients with central nervous system (CNS) metastases from HER2-positive breast cancer after two or more previous HER2-directed regimens, the combination of neratinib plus capecitabine was associated with improved progression-free survival and CNS outcomes compared with lapatinib plus capecitabine. These findings build on previous phase II and III studies describing efficacy of neratinib in the prevention and treatment of CNS metastases, and support a role for neratinib as a systemic treatment option in the management of patients with HER2-positive brain metastases following antibody-based HER2-directed therapies. This study aimed to investigate the expression of Williams Syndrome transcription factor (WSTF) in cervical cancer (CC) tissues and cells, the effect on the proliferation, migration, invasion, and the molecular mechanism of WSTF in CC cells to find a new biomarker. The expression of WSTF in tissues was detected by real-time quantitative polymerase chain reaction (RT-qPCR) and/or immunohistochemistry. Human CC cell lines and human normal cervical epithelial cell lines were detected by RT-qPCR. Lentivirus-mediated gene transfected in Siha/CaSki cells. The transfection efficiency of lentivirus was observed by a fluorescence microscope, RT-qPCR, and western blot. After transfection, the proliferation of Siha/CaSki cells was detected by CCK-8 assay and colony formation assay. The migration and invasion of Siha/CaSki cells were detected by transwell assay and wound healing assay. Western blot assay were used to detect the expression of WSTF and PI3K/Akt-related proteins in Siha/CaSki cells. The expression of WSTF in CC tissues wa